<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04398485</url>
  </required_header>
  <id_info>
    <org_study_id>ION251-CS1</org_study_id>
    <nct_id>NCT04398485</nct_id>
  </id_info>
  <brief_title>A Study of ION251 Administered to Patients With Relapsed/Refractory Multiple Myeloma</brief_title>
  <official_title>A Phase 1 Study of ION251 Administered by Intravenous Infusion to Patients With Relapsed/Refractory Multiple Myeloma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ionis Pharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ionis Pharmaceuticals, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the maximum-tolerated dose (MTD) and recommended&#xD;
      Phase 2 dose (RP2D) of ION251 in patients with relapsed/refractory multiple myeloma.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a two-part, multi-center first in human study of ION251 in up to 80 participants.&#xD;
      Part 1 will use a 3+3 dose-escalation scheme in sequential cohorts to determine the MTD and&#xD;
      RP2D during repeated 28-day treatment cycles. MTD will be determined by the number of&#xD;
      participants with AEs meeting the dose-limiting toxicity (DLT) criteria during Cycle 1. The&#xD;
      MTD determined in Part 1 will be used with other variables to inform a RP2D for participants&#xD;
      proceeding to Part 2 for further assessments in the safety, tolerability and anti-myeloma&#xD;
      activity.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 20, 2021</start_date>
  <completion_date type="Anticipated">January 2024</completion_date>
  <primary_completion_date type="Anticipated">January 2024</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum-Tolerated Dose (MTD)</measure>
    <time_frame>Up to 28 days from the last dose of study drug in Cycle 1 (each cycle is 28 days)</time_frame>
    <description>MTD is defined as the maximum dose at which ≤ 1 of 3 evaluable participants experiences a dose-limiting toxicity (DLT) within Cycle 1 and there are 2 of 3 or 2 of 6 evaluable participants in the next higher-dose level experiencing a DLT within Cycle 1. If no dose in the dose-escalation has 2 of 3 or 2 of 6 evaluable participants experiencing a DLT, the highest dose level is considered the MTD</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Recommended Phase 2 Dose (PR2D)</measure>
    <time_frame>Up to 28 days from the last dose of study drug</time_frame>
    <description>RP2D is chosen based on the dose response and exposure-response analyses of the pooled clinical PK, PD, safety results, and anti-myeloma activity from both Part 1 and Part 2</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety and Tolerability as Measured by the Incidence of TEAEs</measure>
    <time_frame>Up to 28 days from the last dose of study drug</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Abnormal Laboratory Values and Vital Signs</measure>
    <time_frame>Up to 28 days from the last dose of study drug</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cmax: Maximum Observed Concentration ION251</measure>
    <time_frame>From Baseline up to 28 days from the last dose of study drug</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC[0-t]: Area Under the Plasma Concentration-Time Curve from Hour zero to t of ION251</measure>
    <time_frame>From Baseline up to 28 days from the last dose of study drug</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>t1/2: Distribution Half-life of ION251</measure>
    <time_frame>From Baseline up to 28 days from the last dose of study drug</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Trough Concentration of ION251</measure>
    <time_frame>From Baseline up to 28 days from the last dose of study drug</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Urine 0-24 Hour (hr) Excretion of ION251</measure>
    <time_frame>Up to 12 months from the last dose of study drug</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Relapsed Multiple Myeloma</condition>
  <condition>Refractory Multiple Myeloma</condition>
  <arm_group>
    <arm_group_label>ION251</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>In Part 1, the dose escalation phase, increased amounts of ION251 will be administered at multiple time points by intravenous (IV) infusion during 28-day cycles. In Part 2, the determined RP2D of ION251 will be administered at multiple time points by IV infusion.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ION251</intervention_name>
    <description>ION251 administered by IV infusion</description>
    <arm_group_label>ION251</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Aged ≥ 18 years at the time of informed consent&#xD;
&#xD;
          2. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1&#xD;
&#xD;
          3. Measurable multiple myeloma (MM)&#xD;
&#xD;
          4. In need of systemic treatment for MM and either is refractory to or has failed&#xD;
             treatment with, is intolerant to or has refused, or is not otherwise a candidate in&#xD;
             the opinion of the Investigator, for any of the currently available established&#xD;
             therapies known to provide clinical benefit in relapsed/refractory MM. Refractory to&#xD;
             treatment is defined as documented MM disease progression while on or within 60 days&#xD;
             from the last dose (LD) of treatment&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Screen laboratory results as follows, or any other clinically significant&#xD;
             abnormalities in screen laboratory values that would render a participant unsuitable&#xD;
             for inclusion&#xD;
&#xD;
               -  Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) &gt; 2 × upper&#xD;
                  limit of normal (ULN)&#xD;
&#xD;
               -  Total bilirubin &gt; 1.3 × ULN&#xD;
&#xD;
               -  Absolute neutrophil count ≤ 1.0 1000/cubic millimeter (k/mm^3)&#xD;
&#xD;
               -  Platelet count &lt; 50 k/mm^3&#xD;
&#xD;
               -  Hemoglobin &lt; 8.0 g/dL&#xD;
&#xD;
               -  Estimated glomerular filtration rate (eGFR) &lt; 50 milliliters per minute&#xD;
                  (mL/min)/1.73 square meter (m^2)&#xD;
&#xD;
               -  Urine albumin creatinine ratio &gt; 100 mg/g&#xD;
&#xD;
          2. History of or current plasma cell leukemia, POEMS (polyneuropathy, organomegaly,&#xD;
             endocrinopathy, and skin changes) syndrome, solitary bone or extramedullary&#xD;
             plasmacytoma as the only evidence for plasma cell dyscrasia, myelodysplastic syndrome&#xD;
             or a myeloproliferative neoplasm&#xD;
&#xD;
          3. Uncontrolled hypertension (systolic pressure ≥ 160 mm of mercury (mm Hg) and/or&#xD;
             diastolic pressure ≥ 100 mm Hg)&#xD;
&#xD;
          4. Presence of a bleeding disorder or an underlying disease state associated with active&#xD;
             bleeding.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Ionis Pharmaceuticals</last_name>
    <phone>(844) 923-2998</phone>
    <email>ionisNCT04398485study@clinicaltrialmedia.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>The University of Alabama at Birmingham Comprehensive Cancer Center</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35233</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic - Arizona</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85054</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of California San Diego Moores Cancer Center</name>
      <address>
        <city>La Jolla</city>
        <state>California</state>
        <zip>92093</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Cedars-Sinai Medical Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90048</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic - Jacksonville</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32224</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Regional Cancer Care Associates - Center for Cancer and Blood Disorders - Bethesda</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20817</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>The Center for Cancer and Blood Disorders</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20817</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic - Rochester</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Washington University School of Medicine in Saint Louis</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63130</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>New York Presbyterian Hospital</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Levine Cancer Institute</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28204</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Froedtert Hospital</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>53226</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>May 11, 2020</study_first_submitted>
  <study_first_submitted_qc>May 18, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">May 21, 2020</study_first_posted>
  <last_update_submitted>October 13, 2021</last_update_submitted>
  <last_update_submitted_qc>October 13, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 14, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>multiple myeloma</keyword>
  <keyword>Relapsed Multiple Myeloma</keyword>
  <keyword>Refractory Multiple Myeloma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

